Trouver un exemplaire dans la bibliothèque
Recherche de bibliothèques qui possèdent cet ouvrage...
|Type d’ouvrage :||Thèse/mémoire, Manuscrit|
|Format :||Livre, Document mixte|
|Tous les auteurs / collaborateurs :||
Jeffrey L Furman
|Numéro OCLC :||50306058|
|Description :||177 leaves : illustrations ; 29 cm|
|Responsabilité :||by Jeffrey L. Furman.|
(Cont.) The first paper in this dissertation (a) expands the geographic scope of this work to consider whether empirical regularities identified for the United States obtain in other national contexts and (b) addresses methodological issues relevant for assessing the importance of geographic influences on firm profits. The empirical analysis corroborates previous results for the United States - business-specific effects predominate in explaining variance in profits, although industry and corporate parent effects are significant and of important magnitude. Cross-national comparisons demonstrate that this general pattern obtains for samples of firms from Australia, Canada, and the United Kingdom, although results do vary across country. Estimates on national sub-samples of firms in the manufacturing sector provide further evidence of cross-country differences and imply that theories explaining differences in the locus of profitability across countries must operate at levels less aggregate than the national level. In motivating the analysis, the paper describes methodological and analytical considerations that arise from incorporating regional influences into profit decomposition. The second essay exploits a novel dataset to evaluate the separate impacts of firm effects and location effects on organizational practice in pharmaceutical research laboratories. Simultaneously examining the relative salience of firm and location effects enables the paper to assess quantitatively how multiple environments shape organizational characteristics. The results indicate that both firm-specific and location-specific effects have a significant and quantitatively important impact on the extent to which laboratories engage in science-driven drug discovery, a practice associated with enhanced research productivity in the 1980s and 1990s ...